GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (NAS:AKBA) » Definitions » Price-to-Owner-Earnings

Akebia Therapeutics (Akebia Therapeutics) Price-to-Owner-Earnings : (As of Apr. 27, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics Price-to-Owner-Earnings?

As of today (2024-04-27), Akebia Therapeutics's share price is $1.34. Akebia Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Akebia Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:

During the past 12 years, the highest Price-to-Owner-Earnings of Akebia Therapeutics was 21.01. The lowest was 16.47. And the median was 17.51.


AKBA's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 31.62
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-27), Akebia Therapeutics's share price is $1.34. Akebia Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.28. Therefore, Akebia Therapeutics's PE Ratio for today is At Loss.

As of today (2024-04-27), Akebia Therapeutics's share price is $1.34. Akebia Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.28. Therefore, Akebia Therapeutics's PE Ratio without NRI for today is At Loss.


Akebia Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Akebia Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics Price-to-Owner-Earnings Chart

Akebia Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Akebia Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Akebia Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Akebia Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akebia Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akebia Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Price-to-Owner-Earnings falls into.



Akebia Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Akebia Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.34/-0.18
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akebia Therapeutics  (NAS:AKBA) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Akebia Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Akebia Therapeutics (Akebia Therapeutics) Business Description

Traded in Other Exchanges
Address
245 First Street, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.
Executives
Ellen Snow officer: SVP, CFO and Treasurer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Michel Dahan officer: SVP, Chief Business Officer C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Nicole R. Hadas officer: SVP, General Counsel, Sec. 20 PILGRAM DRIVE, WINCHESTER MA 01890
David A Spellman officer: SVP, CFO and Treasurer 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Steven Keith Burke officer: SVP, Chief Medical Officer 82 WILLIS ROAD, SUDBURY MA 01776
John P. Butler director, officer: CEO & President C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Violetta Cotreau officer: SVP, Chief Accounting Officer 245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142
Ron Frieson director 245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142
Dell Faulkingham officer: CCO C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Leanne M Zumwalt director C/O THE ADVISORY BOARD CO WATERGATGE, 600 NEW HAMPSHIRE AVE NW, WASHINGTON DC 20037
Maxine Gowen director
Cynthia Smith director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Myles Wolf director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Karen L Tubridy officer: SVP, Chief Development Officer ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142